DETQ

DETQ is an experimental drug which acts as a positive allosteric modulator of the Dopamine receptor D1. It increases the D1-mediated response to endogenous dopamine levels, and was developed as a potential treatment for Parkinson's disease.^{[1][2][3][4][5]}

DETQ

Identifiers
IUPAC name 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(2-hydroxypropan-2-yl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone
CAS Number	1638667-81-8
PubChem CID	117720272
ChemSpider	58987054
ChEMBL	ChEMBL3421730
Chemical and physical data
Formula	C22H25Cl2NO3
Molar mass	422.35 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@H]1C2=C(C[C@@H](N1C(=O)CC3=C(C=CC=C3Cl)Cl)CO)C(=CC=C2)C(C)(C)O
InChI InChI=1S/C22H25Cl2NO3/c1-13-15-6-4-7-18(22(2,3)28)16(15)10-14(12-26)25(13)21(27)11-17-19(23)8-5-9-20(17)24/h4-9,13-14,26,28H,10-12H2,1-3H3/t13-,14+/m0/s1 Key:CWRORBWPLQQFMX-UONOGXRCSA-N

See also

• Glovadalen
• Mevidalen